STEM-PD enters a new chapter as Cellular Intelligence acquires global rights to advance the stem cell therapy for Parkinson's Disease
The STEM PD clinical trial, a stem cell–based approach for Parkinson’s disease, is entering a new phase in its development. In May 2026, Cellular Intelligence, an AI native biotech company, announced that it has acquired global rights from the Danish pharmaceutical company, Novo Nordisk, to further advance the clinical development of the STEM PD programme. STEM‑PD is among a small number of plurip
